- Home
- COPR vs TLPH Comparison
COPR vs TLPH Comparison
Compare COPR & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COPR | TLPH |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.7M | 70.3M |
| IPO Year | 2008 | 2010 |
Fundamental Metrics
Financial Performance| Metric | COPR | TLPH |
|---|---|---|
| Price | $3.19 | $1.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.13 |
| AVG Volume (30 Days) | 81.3K | ★ 103.1K |
| Earning Date | 12-01-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $609,174.00 | ★ $2,151,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.05 | $0.69 |
| 52 Week High | $4.16 | $1.57 |
Technical Indicators
Market Signals| Indicator | COPR | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 40.32 |
| Support Level | N/A | $1.11 |
| Resistance Level | N/A | $1.29 |
| Average True Range (ATR) | 0.00 | 0.03 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 4.55 |
Price Performance
Historical ComparisonAbout COPR Idaho Copper Corporation Common Stock
Idaho Copper Corp is a USA-based company focused on exploring and developing its copper-molybdenum-silver deposit in Idaho, known as the CuMo project. The CuMo project currently consists of several federal unpatented lode mining claims and various patented mining claims. The unpatented lode mining claims and patented claims are situated in an unorganized mining district, in Boise County, Idaho, spanning Sections in Township 7N and 8N, Range 5E and 6E, Boise Meridian.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.